Korea's SonoCareLab raises seed round from Bluepoint for ultrasound brain device
What's the deal? SonoCareLab, a South Korean startup building ultrasound medical devices for brain disorders, has raised a seed round led by deep-tech accelerator Bluepoint PartnersDealroom has a profile for this one. Try Dealroom →, the company announced on October 29. The round size and valuation were not disclosed.
What's the endgame? The company is developing a device that uses ultrasound to control the brain's glymphatic system, which clears metabolic waste through the circulation of cerebrospinal fluid. Its core "Acoustic Brain Sweeper" technology moves ultrasound in a set direction to stimulate that clearance pathway and boost waste removal.
SonoCareLab plans to position the device as a companion device used alongside antibody drugs, supporting waste clearance to improve treatment efficiency.
Why now? Alzheimer's treatment has shifted with the arrival of antibody therapies such as lecanemab and donanemab, which target amyloid beta. SonoCareLab argues that further gains require addressing how waste leaves the brain, not just the drugs themselves.
The startup was founded on brain-treatment ultrasound technology developed by professor Park Jin-hyung of Sungkyunkwan University's global biomedical engineering department during a Samsung future technology project. Park earned a biomedical engineering doctorate at the University of Southern California and later led ultrasound development at Siemens' Korea lab and at PhilipsDealroom has a profile for this one. Try Dealroom → in the US.
What they said: "Central nervous system disorders including Alzheimer's remain an area of large unmet medical need, requiring new therapeutic approaches beyond drug treatment," said Park Soo-yong, a director at Bluepoint. Chief executive Park Jin-hyung said the plan is to "first enter the antibody-therapy companion device market" and, over the long term, grow into a platform used across various central nervous system diseases.
The signal: Focused ultrasound is drawing renewed investment as researchers test whether it can treat brain disorders or open the blood–brain barrier to improve drug delivery. France's CarThera raised €9 million in October 2026 to advance its SonoCloud platform, a comparable bet in the same field. The area remains clinically high-risk — feasibility has been shown, but randomised evidence of better patient outcomes is still the key hurdle — making SonoCareLab's seed round an early wager in a technically demanding space.
Read more: wowtale.net
Image credit: Generated with Gemini
